Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Manufacturer savings programs reduce expenses to $25 monthly for eligible patients
The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
Annual Review of Pharmacology and Toxicology
We believe that sustainable weight loss is built on a foundation of empathy and clear communication
Document review Request current COA, HPLC chromatogram, MS identity support, SDS, storage notes, salt or counter-ion context, and batch-specific label details before approval
Highlights of Prescribing Information for Wegovy
US$ 25.31
US$ 23.70
US$ 29.21
US$ 23.13
US$ 26.61
US$ 23.37
US$ 25.98
US$ 26.61
